Back to search

Article

A protocol for a systematic review with prospective individual patient data meta-analysis in EGFR mutant NSCLC with brain metastases to assess the effect of SRS + Osimertinib compared to Osimertinib alone: the STARLET collaboration

2023-07-31

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Patients with advanced non-small-cell lung cancer (NSCLC) with activating mutations in the epidermal growth factor receptor ( EGFR ) gene are a heterogenous population who often develop brain metastases (BM). The optimal management of patients with asymptomatic brain metastases is unclear given the activity of newer generation targeted therapies in the central nervous system....

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
370dcaa2-f558-5f2a-92b8-3c4f3f927f32
DOI
10.1101/2023.07.30.23293383
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A protocol for a systematic review with prospective individual patient data meta-analysis in EGFR mutant NSCLC with brain metastases to assess the effect of SRS + Osimertinib compared to Osimertinib alone: the STARLET collaborationDOI 10.1101/2023.07.30.23293383
Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS+osimertinib compared to osimertinib alone: the STARLET Collaboration.Semantic proximity
Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: The STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials.Semantic proximity
Role of osimertinib plus brain radiotherapy versus osimertinib single therapy in EGFR-mutated non-small-cell lung cancer with brain metastases: A meta-analysis and systematic review.Semantic proximity
In-depth exploration of the focus issues of TKI combined with radiotherapy for EGFR-mutant lung adenocarcinoma patients with brain metastasis: a systematic analysis based on literature metrology, meta-analysis, and real-world observational data.Semantic proximity
Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses.Semantic proximity
Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study.Semantic proximity
The Optimal Therapeutic Strategy for Patients with EGFR-Mutated Non–Small Cell Lung Cancer with Brain Metastasis: A Real-World Study from TaiwanSemantic proximity
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.Semantic proximity
Combined BBB-penetrant tyrosine kinase inhibitor and intracranial radiotherapy versus BBB-penetrant tyrosine kinase inhibitor alone for the treatment of EGFR-mutated non-small cell lung cancer patients with brain metastasesSemantic proximity
Comparative efficacy of osimertinib with and without radiation therapy in EGFR-mutated nonsmall cell lung cancer with brain metastases.Semantic proximity
Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: A systematic review and meta-analysis of multidisciplinary approaches.Semantic proximity
Comparing the Effectiveness and Safety of First-line Interventions in Patients With Advanced Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer, With Particular Focus on Brain Metastatic Status: A Systematic Review and Network Meta-analysis.Semantic proximity
Select a neighboring publication to make it the new centre.